Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.67 |
| ▸ | ANPEP | P15144 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | SCN4A | P35499 | 2/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19710825 | 1.00 | EPHX1 (0.67) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| SCHEMBL989960 | 0.84 | EPHX1 (0.70) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| SCHEMBL10005631 | 0.84 | EPHX1 (0.70) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| SCHEMBL28656 | 0.81 | EPHX1 (1.00) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| SCHEMBL21918912 | 0.81 | EPHX1 (0.64) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| SCHEMBL21065978 | 0.79 | EPHX1 (0.61) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| SCHEMBL20717822 | 0.79 | EPHX1 (0.61) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| SCHEMBL13730908 | 0.79 | EPHX1 (0.61) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| Hydrochloric Acid SCHEMBL9402300 | 0.79 | EPHX1 (0.94) | EPHX1ANPEPSLC6A4SLC6A2TAAR1 | |
| SCHEMBL21510397 | 0.77 | FDPS (0.46) | CYP2A6CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8212052-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8106082-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7989484-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110021585-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7834041-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090270473-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-10-29 | — | — | US | disclosed |
| US-20090149521-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090093417-A1 | Dual-acting antihypertensive agents | THERAVANCE, INC. | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093417-A1 | Dual-acting antihypertensive agents | AGTR1, REN, AGTR2 | EPHX1 1488/4885ANPEP 107/4885SLC6A4 225/4885 |
| US-20110021585-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | EPHX1 1488/4885ANPEP 107/4885SLC6A4 225/4885 |
| US-20090270473-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | EPHX1 1053/4885ANPEP 55/4885SLC6A4 221/4885 |
| US-20090149521-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | EPHX1 2027/4885ANPEP 96/4885SLC6A4 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.